Oxford COVID-vaccine paper highlights lingering unknowns about results.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Analyzing the vaccination debate in social media data Pre- and Post-COVID-19 pandemic.International journal of applied earth observation and geoinformation : ITC journal · 2022
   Article
2. SARS-CoV-2: vaccinology and emerging therapeutics; challenges and future developments.Therapeutic delivery · 2022
   Review
3. Pannexin-1 channel opening is critical for COVID-19 pathogenesis.iScience · 2021
   Article
4. Advances in the design and development of SARS-CoV-2 vaccines.Military Medical Research · 2021
   Review
5. COVID-19: vaccine's progress.Microbial biotechnology · 2021
   Article
6. Workforce geography of older dermatologists during the COVID-19 pandemic.Dermatologic therapy · 2021
   Article
7. Does COVID-19 Vaccination Warrant the Classical Principle "Medicina (Kaunas, Lithuania) · 2021
   Review
8. Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective.Viruses · 2021
   Review
9. Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19.Frontiers in molecular biosciences · 2021
   Review

Corrections and comments

• Comment on
  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.2021

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as